Scientists uncover pathway that affects breast cancer stem cells’ growthJune 2nd, 2009 - 2:21 pm ICT by ANI
Washington, June 2 (ANI): Scientists at the University of Michigan Comprehensive Cancer Center have found that a pathway linked to a gene called PTEN, which is well known to stop or suppress cancer, also affect the growth of breast cancer stem cells.
In the same study, the researchers have also found that a drug that interferes with that pathway can lead to an up to 90 percent decrease in the number of cancer stem cells within a tumour.
Reporting their finding sin the journal PLoS Biology, the researchers pointed out that PTEN is the most frequently inactivated tumour suppressor gene in several cancers, including breast cancer, where it is inactivated in about 40 percent of patients.
The researchers also highlighted the fact that PTEN is linked to poor outcomes and is associated with aggressive cancers resistant to chemotherapy and current targeted therapies.During the study, they deleted PTEN in tumours grown in cell cultures and in mice, and found an increase in the number of stem cells.
Looking at pathways associated with PTEN, the researcher found that a pathway called PI3-K/Akt regulated the cancer stem cell population by activating another stem cell pathway, Wnt, which is also implicated in multiple cancer types.”Although there has been considerable progress in identifying cancer stem cells in a variety of tumor types, the pathways that drive the transformation of these cells are not well understood,” says lead study author Dr. Hasan Korkaya, research investigator in internal medicine at the U-M Medical School.Breast cancer stem cells represent fewer than 5 percent of the cells in a tumour, but are believed to be responsible for fuelling a tumour’s growth and spread. It is believed that the ultimate cure of cancer will require killing these cells.In the current study, the researchers treated tumours in mice with a drug called perifosine, which inhibits the Akt pathway, or docetaxel, a standard chemotherapy drug.
The docetaxel alone showed no effect on the number of cancer stem cells in the tumour. But adding perifosine reduced the cancer stem cell population by up to 90 percent.The researchers also observed that the cells treated with perifosine, either with or without docetaxel, were less likely to grow a secondary tumour, compared to the cells treated with just docetaxel.”This is most exciting since perifosine and other drugs that target this pathway are currently in clinical development. If cancer stem cells do contribute to tumor relapse, then adding drugs that target these cells may help to make our current therapies more effective,” says study senior author Dr. Max S. Wicha, Distinguished Professor of Oncology and director of the U-M Comprehensive Cancer Center. (ANI)
- Combo therapy may overcome Herceptin-resistant breast cancer - Mar 14, 2011
- Potent anticancer drug isolated from weed - Jul 10, 2012
- Scientists pinpoint deadly brain tumor's origin - Jan 08, 2011
- Novel way to kill treatment-resistant breast cancer stem cells - Jan 05, 2010
- Study shows that a new experimental cancer drug delays breast tumor growth - Jun 05, 2012
- New treatment shows promise in the fight against breast cancer - Mar 30, 2011
- Drug used to treat asthma 'prevents spread of breast cancer' - Nov 04, 2010
- Broccoli may help treat breast cancer - May 06, 2010
- Intestinal stem cells offer clues to colon cancer origin and relapse - Mar 18, 2011
- Broccoli may help fight breast cancer - May 04, 2010
- Red wine compound 'can give a boost to breast cancer treatment' - Feb 15, 2011
- Turning off oncogene may inhibit lung cancer stem cells' growth - Sep 09, 2009
- New experimental drug slows down growth of ovarian cancer - Apr 16, 2011
- Prostate and breast cancer usually recur in bone: Study - Mar 24, 2011
- Molecular predictor of metastatic prostate cancer identified - Feb 03, 2011
Tags: akt pathway, breast cancer, cancer types, cell cultures, cell pathway, cell population, comprehensive cancer center, docetaxel, m medical school, michigan comprehensive cancer, perifosine, pi3, plos biology, poor outcomes, pten, research investigator, stem cells, suppressor gene, tumor types, university of michigan comprehensive cancer center